Flexion Therapeutics Gets a Buy Rating from Needham

By Ryan Adsit

In a report issued on September 15, Alan Carr from Needham reiterated a Buy rating on Flexion Therapeutics (NASDAQ: FLXN), with a price target of $36. The company’s shares closed on Friday at $24.12.

According to TipRanks.com, Carr is a 4-star analyst with an average return of 7.3% and a 44.3% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Flexion Therapeutics is Strong Buy and the average price target is $38.75, representing a 60.7% upside.

In a report issued on September 11, RBC Capital also reiterated a Buy rating on the stock with a $44 price target.

The company has a one year high of $29.41 and a one year low of $15.93. Currently, Flexion Therapeutics has an average volume of 536.5K.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FLXN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies. The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D.